Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2020 | Acute Myocardial Infarction and Anemia: Are Transfusions Necessary?

In anemic patients undergoing acute myocardial infarction, a restrictive transfusion strategy is as safe as a more liberal approach, in addition to saving costs. The cutoff value to decide for a transfusion would be < 8 g/dl hemoglobin.

Infarto agudo y anemia ¿es necesaria la transfusión?

The REALITY outcomes were presented during the virtual ESC 2020 sessions.

Anemia is relatively common in patients admitted for acute myocardial infarction (between 5 and 10%).

There are prior randomized studies comparing different strategies in the context of surgery or gastrointestinal bleeding, but patients undergoing MI have historically been excluded.

The REALITY was carried out in France and Spain, it included 630 patients undergoing acute myocardial infarction with hemoglobin between 7 and 10 gr/dl during hospitalization. 

It randomized patients to a restrictive strategy (cutoff <8 gr/dl with a target between 8 and 10 gr/dl) or a more liberal approach (cutoff <10 gr/dl with a target >11 gr/dl).


Read also: ESC 2020 | Revascularization Strategies: Ventricular Dysfunction Might Tilt the Scales.


These strategies were maintained until discharge or 30 days (whatever happened first).

Regardless the strategy, transfusion was allowed in cases of active bleeding, if a significant drop was expected, one that rendered a blood test redundant, or when patients went into shock. 

With the restrictive strategy, 35.7% of patients received at least one transfusion compared against 86.7% of the liberal strategy.


Read also: ESC 2020 | Dapagliflozin in Kidney Failure: The Drug Continues to Conquer Other Territories.


Safety also resulted identical between the groups, but those in the restrictive arm showed fewer infections (0% vs 1.5%) and less pulmonary injury (0.3% vs 2.2%; p=0.03 for both).

The combined primary end point (death, repeat MI, stroke and emergency revascularization) resulted 11% for the restrictive strategy vs. 14% for the conservative.

The restrictive strategy also saved costs and hospital resources.

Original Title: REALITY – a randomized trial of transfusion strategies in patients with myocardial infarction and anemia: 30-day results.

Reference: Steg PG et al. Presentado en forma virtual en ESC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...